CRISPR Therapeutics (CRSP) is emerging as a focal point for investors seeking high-growth potential in the biotech sector, particularly as it ranks as the second-largest holding in Cathie Wood’s Ark Innovation ETF. The company has one approved therapy, Casgevy, developed in partnership with Vertex Pharmaceuticals (VRTX), but faces significant challenges in scaling production and generating profits.

Despite the promise of Casgevy, Vertex has struggled to manufacture the therapy due to difficulties in harvesting viable stem cells from sickle cell disease patients. As of now, Vertex has not reported any profit from Casgevy, raising concerns about CRISPR’s ability to convert its substantial losses—over $664 million last year—into future gains. Competing therapies, such as Genetix’s Lyfgenia, further complicate CRISPR’s market position.

Investors should remain cautious; while CRISPR’s pipeline includes promising candidates like CTX310, which could potentially revolutionize treatment for severe dyslipidemia, further updates are necessary to assess its viability. Patience may be crucial before committing to a position in CRISPR Therapeutics.

Source: fool.com